

TABLE 3—TEST INFORMATION RECEIVED—Continued

Case No.	Received date	Type of test information	Chemical substance
P-25-0100 .....	01/27/2026	Hydrolysis as a Function of pH (OECD Test Guideline 111).	(G) Aromatic sulfonium tricyclo salt with alkyl carbomonocycle hetero acid.
P-25-0102 .....	01/27/2026	Hydrolysis as a Function of pH (OECD Test Guideline 111).	(G) Darboheterocyclic aromatic sulfonium salt with dicycloalkyl carbomonocycle hetero acid.
P-25-0111 .....	01/27/2026	Hydrolysis as a Function of pH (OECD Test Guideline 111).	(G) Haloaromatic iodonium dicyclo salt with polyfluoroalkyl carbomonocycle hetero acid.
P-25-0112 .....	01/27/2026	Hydrolysis as a Function of pH (OECD Test Guideline 111).	(G) Haloaromatic iodonium dicyclo salt with halogenated hydroxyaryl carboxylic acid.
P-25-0124 .....	01/27/2026	Hydrolysis as a Function of pH (OECD Test Guideline 111).	(G) Alkyl aromatic sulfonium, polycyclic alkyl sulfamate.
P-25-0135 .....	01/13/2026	Acute Inhalation Toxicity (OECD Test Guideline 403)	(G) Metal- and metal- and metal-doped cobalt lithium manganese nickel oxide.
P-26-0010 .....	01/07/2026	Acute Toxicity Study .....	(G) Ditridecylamine, isomer mixture.

#### IV. Status Reports

Information about the TSCA section 5 PMNs, SNUNs, MCANs, and exemption applications received, including the date of receipt, the status of EPA's review, the final EPA determination, and the effective date of EPA's determination, is available online at: <https://www.epa.gov/reviewing-new-chemicals-under-toxic-substances-control-act-tsca/status-pre-manufacture-notices>.

Authority: 15 U.S.C. 2601 *et seq.*

Dated: June 1, 2026.

**Mary Elissa Reaves,**  
Director, Office of Pollution Prevention and Toxics.

[FR Doc. 2026-11318 Filed 6-4-26; 8:45 am]

BILLING CODE 6560-50-P

#### FEDERAL MARITIME COMMISSION

[Docket No. 26-08]

##### **Ealytex Global Inc., Complainant v. COSCO Shipping Lines Co., Ltd., Respondent; Notice of Filing of Complaint and Assignment**

Notice is given that a complaint has been filed with the Federal Maritime Commission (the "Commission") by Ealytex Global Inc. (the "Complainant") against COSCO Shipping Lines Co., Ltd. (the "Respondent"). Complainant states that the Commission has jurisdiction over the complaint pursuant to the Shipping Act of 1984, as amended, 46 U.S.C. 40101 *et seq.*, and personal jurisdiction over Respondent as an "ocean common carrier," as that term is defined in 46 CFR 520.2.

Complainant is a corporation organized under the laws of the state of New York with its principal place of business in New York City, New York.

Complainant identifies Respondent as a vessel-operating ocean common carrier, as defined in 46 U.S.C.

40102(18), with its principal place of business located in Shanghai, China, whose agent in the United States is located in Secaucus, New Jersey.

Complainant alleges that Respondent violated 46 U.S.C. 41102(c) and 41104(a)(10), and 46 CFR 545.5. Complainant alleges these violations arose from the assessment of detention and demurrage charges during periods of time in which Complainant's ability to move its containers was constrained due to circumstances beyond its control, the promise of refunds for some of those charges that have remained unfulfilled, the issuance of improper invoices, and other acts or omissions by Respondent.

An answer to the complaint must be filed with the Commission within 25 days after the date of service.

The full text of the complaint can be found in the Commission's electronic Reading Room at <https://www2.fmc.gov/readingroom/proceeding/26-08/>. This proceeding has been assigned to the Office of Administrative Law Judges. The initial decision of the presiding judge shall be issued by June 3, 2027, and the final decision of the Commission shall be issued by December 17, 2027.

(Authority: 46 U.S.C. 41301; 46 CFR 502.61(c))

Served: June 3, 2026.

**David Eng,**  
Secretary.

[FR Doc. 2026-11365 Filed 6-4-26; 8:45 am]

BILLING CODE 6730-02-P

#### FEDERAL RESERVE SYSTEM

##### **Formations of, Acquisitions by, and Mergers of Bank Holding Companies**

##### **Correction**

This corrects notice FR Doc. 2026-11203. Paragraph 1 is corrected to read:

1. *Mascoma Mutual Financial Services Corporation*, ("Mascoma"), *Lebanon, New Hampshire*; to merge with *Androscoggin Bancorp, MHC*, and thereby indirectly acquire *Androscoggin Bancorp, Inc.*, and *Androscoggin Savings Bank*, all of *Lewiston, Maine*. In addition, *Mascoma*, through the acquisition of *Portland Trust Company, LLC*, *Portland, Maine*, would engage in providing trust company functions pursuant to section 225.28(b)(5) of the Board's Regulation Y.

Board of Governors of the Federal Reserve System.

**Michele Taylor Fennell,**  
Associate Secretary of the Board.

[FR Doc. 2026-11355 Filed 6-4-26; 8:45 am]

BILLING CODE P

#### FEDERAL RESERVE SYSTEM

##### **Formations of, Acquisitions by, and Mergers of Bank Holding Companies**

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 *et seq.*) (BHC Act), Regulation Y (12 CFR part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The public portions of the applications listed below, as well as other related filings required by the Board, if any, are available for immediate inspection at the Federal Reserve Bank(s) indicated below and at the offices of the Board of Governors. This information may also be obtained on an expedited basis, upon request, by contacting the appropriate Federal

Reserve Bank and from the Board's Freedom of Information Office at <https://www.federalreserve.gov/foia/request.htm>. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)).

Comments received are subject to public disclosure. In general, comments received will be made available without change and will not be modified to remove personal or business information including confidential, contact, or other identifying information. Comments should not include any information such as confidential information that would not be appropriate for public disclosure.

Comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors, Benjamin W. McDonough, Secretary of the Board, 20th Street and Constitution Avenue NW, Washington, DC 20551-0001, not later than July 6, 2026.

*A. Federal Reserve Bank of Atlanta* (Erien O. Terry, Assistant Vice President) 1000 Peachtree Street NE, Atlanta, Georgia 30309. Comments can also be sent electronically to [Applications.Comments@atl.frb.org](mailto:Applications.Comments@atl.frb.org):

1. *Juno Bancorp, Inc., Palm Beach Gardens, Florida*; to become a bank holding company by acquiring New Republic Bank, Charlotte, North Carolina.

*B. Federal Reserve Bank of Chicago* (Colette A. Fried, Assistant Vice President) 230 South LaSalle Street, Chicago, Illinois 60690-1414. Comments can also be sent electronically to

[Comments.applications@chi.frb.org](mailto:Comments.applications@chi.frb.org):

1. *Hometown Community Bancorp, Inc., and Hometown Community Bancorp, Inc. Employee Stock Ownership Plan and Trust, both of Morton, Illinois*; to acquire First Bank of Manhattan, Manhattan, Illinois.

2. *OakNorth UK Holdings Limited, London, United Kingdom; OakNorth Holdings Limited, St. Helier, Jersey; OakNorth Interim Holdings Limited, London, United Kingdom; and OakNorth U.S. Holdings LLC, Wilmington, Delaware*; to become bank holding companies by acquiring Community Unity Bank and OakNorth Interim Bank, National Association, both of Birmingham, Michigan.

Board of Governors of the Federal Reserve System.

**Michele Taylor Fennell,**

*Associate Secretary of the Board.*

[FR Doc. 2026-11354 Filed 6-4-26; 8:45 am]

**BILLING CODE P**

## DEPARTMENT OF HEALTH AND HUMAN SERVICES

### Food and Drug Administration

[Docket No. FDA-2014-D-0967]

#### Intent To Exempt Certain Unclassified Medical Devices From Premarket Notification Requirements; Guidance for Industry and Food and Drug Administration Staff; Availability

**AGENCY:** Food and Drug Administration, HHS.

**ACTION:** Notice of availability.

**SUMMARY:** The Food and Drug Administration (FDA) is announcing the availability of the guidance "Intent to Exempt Certain Unclassified Medical Devices from Premarket Notification Requirements." This guidance describes FDA's intent to exempt certain unclassified medical devices from premarket notification requirements. At this time, and based on the information currently available to the Agency, FDA believes the devices identified in this guidance meet the standards for exemption from premarket notification. This guidance has been implemented without prior comment, but it remains subject to comment in accordance with the Agency's good guidance practices.

**DATES:** The announcement of the guidance is published in the **Federal Register** on June 5, 2026.

**ADDRESSES:** You may submit either electronic or written comments on Agency guidances at any time as follows:

#### *Electronic Submissions*

Submit electronic comments in the following way:

- *Federal eRulemaking Portal:* <https://www.regulations.gov>. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to <https://www.regulations.gov> will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else's Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on <https://www.regulations.gov>.

- If you want to submit a comment with confidential information that you do not wish to be made available to the

public, submit the comment as a written/paper submission and in the manner detailed (see "Written/Paper Submissions" and "Instructions").

#### *Written/Paper Submissions*

Submit written/paper submissions as follows:

- *Mail/Hand delivery/Courier (for written/paper submissions):* Dockets Management Staff (HFA-305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.

- For written/paper comments submitted to the Dockets Management Staff, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in "Instructions."

*Instructions:* All submissions received must include the Docket No. FDA-2014-D-0967 for "Intent to Exempt Certain Unclassified Medical Devices from Premarket Notification Requirements." Received comments will be placed in the docket and, except for those submitted as "Confidential Submissions," publicly viewable at <https://www.regulations.gov> or at the Dockets Management Staff between 9 a.m. and 4 p.m., Monday through Friday, 240-402-7500.

- *Confidential Submissions—*To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states "THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION." The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on <https://www.regulations.gov>. Submit both copies to the Dockets Management Staff. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as "confidential." Any information marked as "confidential" will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA's posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: <https://www.govinfo.gov/content/pkg/FR-2015-09-18/pdf/2015-23389.pdf>.